Review on Experimental Treatment Strategies Against Trypanosoma cruzi

References

• Chagas C. Nova tripanozomiaze humana: estudos sobre a morfolojia e o ciclo evolutivo do Schizotrypanum cruzi n. gen., n. sp., ajente etiolojico de nova entidade morbida do homem. Mem Inst Oswaldo Cruz. 1909;1(2):159–218. doi:10.1590/S0074-02761909000200008
   Google Scholar
• WHO Chagas disease (American trypanosomiasis). 2020. Available from: https://www.who.int/westernpacific/health-topics/chagas-disease. Accessed November 20, 2020
   Google Scholar
• Lidani KCF, Andrade FA, Bavia L, et al. Chagas disease: from discovery to a worldwide health problem. Front Public Health. 2019;7:166. doi:10.3389/fpubh.2019.00166
   PubMed Web of Science ®Google Scholar
• Guhl F, Ramírez JD. Poverty, migration, and chagas disease. Curr Trop Med Rep. 2021. doi:10.1007/s40475-020-00225-y
   Google Scholar
• Brener Z. Biology of Trypanosoma Cruzi. Annu Rev Microbiol. 1973;27(1):347–382. doi:10.1146/annurev.mi.27.100173.002023
   PubMed Web of Science ®Google Scholar
• Carlier Y, Torrico F. Congenital infection with Trypanosoma cruzi: from mechanisms of transmission to strategies for diagnosis and control. Rev Soc Bras Med Trop. 2003;36(6):767–771. doi:10.1590/S0037-86822003000600024
   PubMedGoogle Scholar
• Howard JE, Rios C, Ebensperger I, Olivos P. [Congenital Chagas’ disease]. Bol Chil Parasitol. 1957;12(3):42–45.
   PubMedGoogle Scholar
• Wanderley DM, Aranha Camargo LM, de Carvalho ME. [Chagas’ disease: registry of an acute transfusional case]. Rev Inst Med Trop Sao Paulo. 1988;30(6):437–440. doi:10.1590/s0036-46651988000600009
   Web of Science ®Google Scholar
• Dias JCP, Amato Neto V. [Prevention concerning the different alternative routes for transmission of Trypanosoma cruzi in Brazil]. Rev Soc Bras Med Trop. 2011;44(Suppl 2):68–72. doi:10.1590/s0037-86822011000800011
   Web of Science ®Google Scholar
• Dias JCP. Notas sobre o Trypanosoma cruzi e suas características bio-ecológicas, como agente de enfermidades transmitidas por alimentos. Rev Soc Bras Med Trop. 2006;39(4):370–375. doi:10.1590/s0037-86822006000400010
   Web of Science ®Google Scholar
• Pereira KS, Schmidt FL, Guaraldo AMA, Franco RMB, Dias VL, Passos LAC. Chagas’ disease as a foodborne illness. J Food Prot. 2009;72(2):441–446. doi:10.4315/0362-028x-72.2.441
   Web of Science ®Google Scholar
• Coura JR, Viñas PA, Junqueira AC. Ecoepidemiology, short history and control of Chagas disease in the endemic countries and the new challenge for non-endemic countries. Mem Inst Oswaldo Cruz. 2014;109(7):856–862. doi:10.1590/0074-0276140236
   PubMed Web of Science ®Google Scholar
• Alarcón de Noya B, Díaz‐Bello Z, Colmenares C, et al. Large urban outbreak of orally acquired acute chagas disease at a school in Caracas, Venezuela. J INFECT DIS. 2010;201(9):1308–1315. doi:10.1086/651608
   PubMed Web of Science ®Google Scholar
• da Brasil MS. Boletim Epidemiológico - Doença de Chagas aguda no Brasil: série histórica de 2000 a 2013. 2015;46(21):1–9.
   Google Scholar
• Ríos JF, Arboleda M, Montoya AN, Alarcón EP. [Probable outbreak of oral transmission of Chagas disease in Turbo, Antioquia]. Biomedica. 2011;31(2):185–195. doi:10.1590/S0120-41572011000200005
   Web of Science ®Google Scholar
• Shikanai-Yasuda MA, Carvalho NB. Oral transmission of chagas disease. Clin Infect Dis. 2012;54(6):845–852. doi:10.1093/cid/cir956
   PubMed Web of Science ®Google Scholar
• Rassi A, Rassi A. Marcondes de Rezende J. American Trypanosomiasis (Chagas Disease). Infect Dis Clin North Am. 2012;26(2):275–291. doi:10.1016/j.idc.2012.03.002
   PubMed Web of Science ®Google Scholar
• Pérez-Molina JA, Molina I. Chagas disease. The Lancet. 2018;391(10115):82–94. doi:10.1016/S0140-6736(17)31612-4
   PubMed Web of Science ®Google Scholar
• Barrett MP, Burchmore RJS, Stich A, et al. The trypanosomiases. Lancet. 2003;362(9394):1469–1480. doi:10.1016/S0140-6736(03)14694-6
   PubMed Web of Science ®Google Scholar
• Remme JHF, Feenstra P, Lever PR, et al.. Tropical diseases targeted for elimination: chagas disease, lymphatic filariasis, onchocerciasis, and leprosy. In: Jamison DT, Breman JG, Measham AR, et al., editors. Disease Control Priorities in Developing Countries. 2nd ed. World Bank; 2006. Available from: http://www.ncbi.nlm.nih.gov/books/NBK11745/. Accessed November 24, 2020.
   Google Scholar
• Salomao K, Figueiredo Sadok Menna-Barreto R, Lisboa de Castro S. Stairway to heaven or hell? Perspectives and limitations of chagas disease chemotherapy. CTMC. 2016;16(20):2266–2289. doi:10.2174/1568026616666160413125049
   Web of Science ®Google Scholar
• Dias JC. The indeterminate form of human chronic Chagas’ disease. A clinical epidemiological review. Rev Soc Bras Med Trop. 1989;22(3):147–156. doi:10.1590/s0037-86821989000300007
   PubMedGoogle Scholar
• Salvador F, Treviño B, Sulleiro E, et al. Trypanosoma cruzi infection in a non-endemic country: epidemiological and clinical profile. Clin Microbiol Infect. 2014;20(7):706–712. doi:10.1111/1469-0691.12443
   Web of Science ®Google Scholar
• Chapadeiro E. Clinical evolution and morbi-mortality in Chagas disease. Mem Inst Oswaldo Cruz. 1999;94(Suppl 1):309–310. doi:10.1590/s0074-02761999000700058
   Web of Science ®Google Scholar
• Nunes MCP, Do Carmo AAL, Rocha MOC, Ribeiro AL. Mortality prediction in Chagas heart disease. Expert Rev Cardiovasc Ther. 2012;10(9):1173–1184. doi:10.1586/erc.12.111
   PubMedGoogle Scholar
• Andrade SG, Stocker-Guerret S, Pimentel AS, Grimaud JA. Reversibility of cardiac fibrosis in mice chronically infected with Trypanosoma cruzi, under specific chemotherapy. Mem Inst Oswaldo Cruz. 1991;86(2):187–200. doi:10.1590/s0074-02761991000200008
   PubMed Web of Science ®Google Scholar
• Bahia MT, de Diniz LF, Mosqueira VCF. Therapeutical approaches under investigation for treatment of Chagas disease. Expert Opin Investig Drugs. 2014;23(9):1225–1237. doi:10.1517/13543784.2014.922952
   PubMed Web of Science ®Google Scholar
• Higuchi M, De Brito T, Martins Reis M, et al. Correlation between Trypanosoma cruzi parasitism and myocardial inflammatory infiltrate in human chronic chagasic myocarditis: light microscopy and immunohistochemical findings. Cardiovasc Pathol. 1993;2(2):101–106. doi:10.1016/1054-8807(93)90021-S
   Web of Science ®Google Scholar
• Jones EM, Colley DG, Tostes S, Lopes ER, Vnencak-Jones CL, McCurley TL. Amplification of a Trypanosoma cruzi DNA sequence from inflammatory lesions in human chagasic cardiomyopathy. Am J Trop Med Hyg. 1993;48(3):348–357. doi:10.4269/ajtmh.1993.48.348
   Web of Science ®Google Scholar
• Tarleton RL, Zhang L. Chagas disease etiology: autoimmunity or parasite persistence? Parasitol Today. 1999;15(3):94–99. doi:10.1016/S0169-4758(99)01398-8
   PubMedGoogle Scholar
• Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med. 2006;144(10):724–734. doi:10.7326/0003-4819-144-10-200605160-00006
   PubMed Web of Science ®Google Scholar
• Bock M, Gönnert R, Haberkorn A. Studies with Bay 2502 on animals. Bol Chil Parasitol. 1969;24(1):13–19.
   Google Scholar
• Brener Z. Atividade terapêutica do 5-nitro-furaldeído - semicarbazona (nitrofurazona) em esquemas de duração prolongada na infecção experimental do camundongo pelo Trypanosoma cruzi. Revista Do Instituto De Medicina Tropical De São Paulo. 1961;3:43–49.
   Google Scholar
• Packchanian A. Chemotherapy of experimental Chagas’ disease with nitrofuran compounds. Antibiot Chemother (Northfield). 1957;7(1):13–23.
   Google Scholar
• de Ferreira HO. Ensaio terapêutico-clínico com benzonidazol na doença de chagas. Rev Inst Med Trop São Paulo. 1976;18(5):357–364.
   Google Scholar
• Wilkinson SR, Kelly JM. Trypanocidal drugs: mechanisms, resistance and new targets. Expert Rev Mol Med. 2009;11:e31. doi:10.1017/S1462399409001252
   PubMed Web of Science ®Google Scholar
• Patterson S, Fairlamb AH. Current and future prospects of nitro-compounds as drugs for trypanosomiasis and leishmaniasis. CMC. 2019;26(23):4454–4475. doi:10.2174/0929867325666180426164352
   Web of Science ®Google Scholar
• Maya JD, Cassels BK, Iturriaga-Vásquez P, et al. Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. Comp Biochem Physiol a Mol Integr Physiol. 2007;146(4):601–620. doi:10.1016/j.cbpa.2006.03.004
   PubMed Web of Science ®Google Scholar
• Rajão MA, Furtado C, Alves CL, et al. Unveiling benznidazole’s mechanism of action through overexpression of DNA repair proteins in Trypanosoma cruzi. Environ Mol Mutagen. 2014;55(4):309–321. doi:10.1002/em.21839
   PubMed Web of Science ®Google Scholar
• FDA O of the C. FDA approves first U.S. treatment for Chagas disease. FDA. March 24, 2020. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-us-treatment-chagas-disease Accessed February 5, 2021.
   Google Scholar
• Ribeiro V, Dias N, Paiva T, et al. Current trends in the pharmacological management of Chagas disease. Int J Parasitol Drugs Drug Resist. 2020;12:7–17. doi:10.1016/j.ijpddr.2019.11.004
   PubMed Web of Science ®Google Scholar
• Urbina JA. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop. 2010;115(1–2):55–68. doi:10.1016/j.actatropica.2009.10.023
   PubMed Web of Science ®Google Scholar
• Yun O, Lima MA, Ellman T, et al. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières. PLoS Negl Trop Dis. 2009;3(7):e488. doi:10.1371/journal.pntd.0000488
   PubMed Web of Science ®Google Scholar
• Molina I, Gómez I, Prat J, et al. Randomized trial of posaconazole and benznidazole for chronic Chagas’ disease. N Engl J Med. 2014;370(20):1899–1908. doi:10.1056/NEJMoa1313122
   PubMed Web of Science ®Google Scholar
• Torrico F, Gascon J, Ortiz L, et al. Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial. Lancet Infect Dis. 2018;18(4):419–430. doi:10.1016/S1473-3099(17)30538-8
   PubMed Web of Science ®Google Scholar
• Bahia MT, De andrade IM, Martins TAF, et al. Fexinidazole: a potential new drug candidate for chagas disease. Pollastri MP, ed. PLoS Negl Trop Dis. 2012;6(11):e1870. doi:10.1371/journal.pntd.0001870
   PubMed Web of Science ®Google Scholar
• Francisco AF, Jayawardhana S, Lewis MD, et al. Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage. Sci Rep. 2016;6(1):35351. doi:10.1038/srep35351
   Web of Science ®Google Scholar
• Raether W, Seidenath H. The activity of fexinidazole (HOE 239) against experimental infections with Trypanosoma cruzi, trichomonads and Entamoeba histolytica. Ann Trop Med Parasitol. 1983;77(1):13–26. doi:10.1080/00034983.1983.11811668
   PubMed Web of Science ®Google Scholar
• Bahia MT, Nascimento AFS, Mazzeti AL, et al. Antitrypanosomal activity of fexinidazole metabolites, potential new drug candidates for chagas disease. Antimicrob Agents Chemother. 2014;58(8):4362–4370. doi:10.1128/AAC.02754-13
   PubMed Web of Science ®Google Scholar
• Filardi LS, Brener Z. A nitroimidazole-thiadiazole derivative with curative action in experimental Trypanosoma cruzi infections. Ann Trop Med Parasitol. 1982;76(3):293–297. doi:10.1080/00034983.1982.11687544
   PubMed Web of Science ®Google Scholar
• Andrade SG, Silva RC, Santiago CMG. Freitas L a. R. Therapeutic action of MK-436 (2,5-nitroimidazole) on Trypanosoma cruzi infections in mice: a parasitological, serological, histopathological, and ultrastructural study. Bull World Health Organ. 1987;65(5):625.
   Web of Science ®Google Scholar
• Andrade SG, Silva RC, Santiago CM. Treatment of chronic experimental Trypanosoma cruzi infections in mice with MK-436, a 2-substituted 5-nitroimidazole. Bull World Health Organ. 1989;67(5):509.
   Web of Science ®Google Scholar
• de Castro SL, de Meirelles MN. Mechanism of action of a nitroimidazole-thiadiazole derivate upon Trypanosoma cruzi tissue culture amastigotes. Mem Inst Oswaldo Cruz. 1990;85(1):95–99. doi:10.1590/s0074-02761990000100016
   Web of Science ®Google Scholar
• Salomão K, de Souza EM, Carvalho SA, et al. In vitro and in vivo activities of 1,3,4-thiadiazole-2-arylhydrazone derivatives of megazol against Trypanosoma cruz i. Antimicrob Agents Chemother. 2010;54(5):2023–2031. doi:10.1128/AAC.01241-09
   Web of Science ®Google Scholar
• Sánchez-Moreno M, Gómez-Contreras F, Navarro P, et al. Phthalazine derivatives containing imidazole rings behave as Fe-SOD inhibitors and show remarkable anti-T. cruzi activity in immunodeficient-mouse mode of infection. J Med Chem. 2012;55(22):9900–9913. doi:10.1021/jm3011004
   Web of Science ®Google Scholar
• Bustamante JM, Craft JM, Crowe BD, Ketchie SA, Tarleton RL. New, combined, and reduced dosing treatment protocols cure trypanosoma cruzi infection in mice. J Infect Dis. 2014;209(1):150–162. doi:10.1093/infdis/jit420
   PubMed Web of Science ®Google Scholar
• Moraes CB, Giardini MA, Kim H, et al. Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development. Sci Rep. 2015;4(1):4703. doi:10.1038/srep04703
   Web of Science ®Google Scholar
• Leite DI, de Fontes FV, Bastos MM, et al. New 1,2,3-triazole-based analogues of benznidazole for use against Trypanosoma cruzi infection: in vitro and in vivo evaluations. Chem Biol Drug Des. 2018;92(3):1670–1682. doi:10.1111/cbdd.13333
   PubMed Web of Science ®Google Scholar
• Villalta F, Dobish MC, Nde PN, et al. VNI cures acute and chronic experimental chagas disease. J Infect Dis. 2013;208(3):504–511. doi:10.1093/infdis/jit042
   PubMed Web of Science ®Google Scholar
• Guedes-da-silva FH, Batista DGJ, Da Silva CF, et al. Antitrypanosomal activity of sterol 14α-demethylase (CYP51) inhibitors VNI and VFV in the Swiss mouse models of chagas disease induced by the trypanosoma cruzi Y strain. Antimicrob Agents Chemother. 2017;61(4):e02098-16, e02098-16. doi:10.1128/AAC.02098-16
   PubMed Web of Science ®Google Scholar
• Guedes-da-silva FH, Batista DGJ, da Silva CF, et al. Different therapeutic outcomes of benznidazole and VNI treatments in different genders in mouse experimental models of trypanosoma cruzi infection. Antimicrob Agents Chemother. 2015;59(12):7564–7570. doi:10.1128/AAC.01294-15
   PubMed Web of Science ®Google Scholar
• de Soeiro NC, de Souza EM, da Silva CF, et al. In vitro and in vivo studies of the antiparasitic activity of Sterol 14α-Demethylase (CYP51) Inhibitor VNI against drug-resistant strains of Trypanosoma cruzi. Antimicrob Agents Chemother. 2013;57(9):4151–4163. doi:10.1128/AAC.00070-13
   Web of Science ®Google Scholar
• Keenan M, Alexander PW, Diao H, et al. Design, structure-activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi. Bioorg Med Chem. 2013;21(7):1756–1763. doi:10.1016/j.bmc.2013.01.050
   Web of Science ®Google Scholar
• Keenan M, Abbott MJ, Alexander PW, et al. Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease. J Med Chem. 2012;55(9):4189–4204. doi:10.1021/jm2015809
   PubMed Web of Science ®Google Scholar
• Doyle PS, Chen C-K, Johnston JB, et al. A nonazole CYP51 inhibitor cures Chagas’ disease in a mouse model of acute infection. Antimicrob Agents Chemother. 2010;54(6):2480–2488. doi:10.1128/AAC.00281-10
   Web of Science ®Google Scholar
• Hoekstra WJ, Hargrove TY, Wawrzak Z, et al. Clinical Candidate VT-1161’s antiparasitic effect in vitro, activity in a murine model of chagas disease, and structural characterization in complex with the target enzyme CYP51 from Trypanosoma cruzi. Antimicrob Agents Chemother. 2016;60(2):1058–1066. doi:10.1128/AAC.02287-15
   Web of Science ®Google Scholar
• Calvet CM, Choi JY, Thomas D, et al. 4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection. PLoS Negl Trop Dis. 2017;11(12):e0006132. doi:10.1371/journal.pntd.0006132
   PubMed Web of Science ®Google Scholar
• Papadopoulou MV, Bloomer WD, Rosenzweig HS, et al. Nitrotriazole-based compounds as antichagasic agents in a long-treatment in vivo assay. Antimicrob Agents Chemother. 2017;61(5):e02717-16, e02717-16. doi:10.1128/AAC.02717-16
   PubMed Web of Science ®Google Scholar
• Papadopoulou MV, Bloomer WD, Rosenzweig HS, Wilkinson SR, Szular J, Kaiser M. Nitrotriazole-based acetamides and propanamides with broad spectrum antitrypanosomal activity. Eur J Med Chem. 2016;123:895–904. doi:10.1016/j.ejmech.2016.08.002
   PubMed Web of Science ®Google Scholar
• Papadopoulou MV, Bloomer WD, Rosenzweig HS, et al. Discovery of potent nitrotriazole-based antitrypanosomal agents: in vitro and in vivo evaluation. Bioorg Med Chem. 2015;23(19):6467–6476. doi:10.1016/j.bmc.2015.08.014
   PubMed Web of Science ®Google Scholar
• Papadopoulou MV, Bloomer WD, Rosenzweig HS, O’Shea IP, Wilkinson SR, Kaiser M. 3-Nitrotriazole-based piperazides as potent antitrypanosomal agents. Eur J Med Chem. 2015;103:325–334. doi:10.1016/j.ejmech.2015.08.042
   PubMed Web of Science ®Google Scholar
• Papadopoulou MV, Bloomer WD, Rosenzweig HS, Wilkinson SR, Kaiser M. Novel nitro(triazole/imidazole)-based heteroarylamides/sulfonamides as potential antitrypanosomal agents. Eur J Med Chem. 2014;87:79–88. doi:10.1016/j.ejmech.2014.09.045
   PubMed Web of Science ®Google Scholar
• Papadopoulou MV, Bloomer WD, Rosenzweig HS, et al. Novel 3-nitro-1H-1,2,4-triazole-based compounds as potential anti-Chagasic drugs: in vivo studies. Future Med Chem. 2013;5(15):1763–1776. doi:10.4155/fmc.13.108
   PubMed Web of Science ®Google Scholar
• Papadopoulou MV, Bloomer WD, Rosenzweig HS, Kaiser M, Chatelain E, Ioset J-R. Novel 3-nitro-1H-1,2,4-triazole-based piperazines and 2-amino-1,3-benzothiazoles as antichagasic agents. Bioorg Med Chem. 2013;21(21):6600–6607. doi:10.1016/j.bmc.2013.08.022
   PubMed Web of Science ®Google Scholar
• Papadopoulou MV, Bloomer WD, Rosenzweig HS, et al. Novel 3-nitro-1H-1,2,4-triazole-based amides and sulfonamides as potential antitrypanosomal agents. J Med Chem. 2012;55(11):5554–5565. doi:10.1021/jm300508n
   PubMed Web of Science ®Google Scholar
• Papadopoulou MV, Trunz BB, Bloomer WD, et al. Novel 3-nitro-1H-1,2,4-triazole-based aliphatic and aromatic amines as anti-chagasic agents. J Med Chem. 2011;54(23):8214–8223. doi:10.1021/jm201215n
   PubMed Web of Science ®Google Scholar
• Engel JC, Doyle PS, Hsieh I, McKerrow JH. Cysteine protease inhibitors cure an experimental trypanosoma cruzi infection. J Exp Med. 1998;188(4):725–734. doi:10.1084/jem.188.4.725
   PubMed Web of Science ®Google Scholar
• Doyle PS, Zhou YM, Engel JC, McKerrow JH. A cysteine protease inhibitor cures Chagas’ disease in an immunodeficient-mouse model of infection. Antimicrob Agents Chemother. 2007;51(11):3932–3939. doi:10.1128/AAC.00436-07
   PubMed Web of Science ®Google Scholar
• Barr SC, Warner KL, Kornreic BG, et al. A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi. Antimicrob Agents Chemother. 2005;49(12):5160–5161. doi:10.1128/AAC.49.12.5160-5161.2005
   PubMed Web of Science ®Google Scholar
• Ndao M, Beaulieu C, Black WC, et al. Reversible cysteine protease inhibitors show promise for a chagas disease cure. Antimicrob Agents Chemother. 2014;58(2):1167–1178. doi:10.1128/AAC.01855-13
   PubMed Web of Science ®Google Scholar
• Brak K, Kerr ID, Barrett KT, et al. Nonpeptidic tetrafluorophenoxymethyl ketone cruzain inhibitors as promising new leads for Chagas disease chemotherapy. J Med Chem. 2010;53(4):1763–1773. doi:10.1021/jm901633v
   PubMed Web of Science ®Google Scholar
• de Cardoso MV, de Siqueira LRP, da Silva EB, et al. 2-Pyridyl thiazoles as novel anti-Trypanosoma cruzi agents: structural design, synthesis and pharmacological evaluation. Eur J Med Chem. 2014;86:48–59. doi:10.1016/j.ejmech.2014.08.012
   Web of Science ®Google Scholar
• da Silva EB, Oliveira E, DA S, et al. . Desing and synthesis of potent anti-Trypanosoma cruzi agents new thiazoles derivatives which induce apoptotic parasite death. Eur J Med Chem. 2017;130:39–50. doi:10.1016/j.ejmech.2017.02.026
   PubMed Web of Science ®Google Scholar
• De oliveira Filho GB, de Cardoso MVO, Espíndola JWP, et al. Structural design, synthesis and pharmacological evaluation of thiazoles against Trypanosoma cruzi. Eur J Med Chem. 2017;141:346–361. doi:10.1016/j.ejmech.2017.09.047
   PubMed Web of Science ®Google Scholar
• de Oliveira Filho GB, de Oliveira Cardoso MV, Espíndola JWP, et al. Structural design, synthesis and pharmacological evaluation of 4-thiazolidinones against Trypanosoma cruzi. Bioorg Med Chem. 2015;23(23):7478–7486. doi:10.1016/j.bmc.2015.10.048
   PubMed Web of Science ®Google Scholar
• Soeiro MNC, Werbovetz K, Boykin DW, Wilson WD, Wang MZ, Hemphill A. Novel amidines and analogues as promising agents against intracellular parasites: a systematic review. Parasitology. 2013;140(8):929–951. doi:10.1017/S0031182013000292
   PubMed Web of Science ®Google Scholar
• Da Batista GJ, Batista MM, Oliveira GM, et al. Combined treatment of heterocyclic analogues and benznidazole upon Trypanosoma cruzi in vivo. Moreno SN, ed. PLoS ONE. 2011;6(7):e22155. doi:10.1371/journal.pone.0022155
   Web of Science ®Google Scholar
• Da batista DGJ, Batista MM, De oliveira GM, et al. Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas’ disease treatment. Antimicrob Agents Chemother. 2010;54(7):2940–2952. doi:10.1128/AAC.01617-09
   Web of Science ®Google Scholar
• Liu Z, Wenzler T, Brun R, Zhu X, Boykin DW. Synthesis and antiparasitic activity of new bis-arylimidamides: DB766 analogs modified in the terminal groups. Eur J Med Chem. 2014;83:167–173. doi:10.1016/j.ejmech.2014.06.022
   PubMed Web of Science ®Google Scholar
• da Silva CF, Da Batista DGJ, Oliveira GM, et al. In vitro and in vivo investigation of the efficacy of arylimidamide DB1831 and its mesylated salt form–DB1965–against Trypanosoma cruzi infection. PLoS One. 2012;7(1). doi:10.1371/journal.pone.0030356
   Web of Science ®Google Scholar
• da Silva CF, de Batista DGJ, de Araújo JS, et al. Phenotypic evaluation and in silico ADMET properties of novel arylimidamides in acute mouse models of Trypanosoma cruzi infection. Drug Des Devel Ther. 2017;11:1095–1105. doi:10.2147/DDDT.S120618
   PubMed Web of Science ®Google Scholar
• Timm BL, da Silva PB, Batista MM, et al. In vitro and in vivo biological effects of novel arylimidamide derivatives against Trypanosoma cruzi. Antimicrob Agents Chemother. 2014;58(7):3720–3726. doi:10.1128/AAC.02353-14
   PubMed Web of Science ®Google Scholar
• Álvarez G, Varela J, Cruces E, et al. Identification of a new amide-containing thiazole as a drug candidate for treatment of Chagas’ disease. Antimicrob Agents Chemother. 2015;59(3):1398–1404. doi:10.1128/AAC.03814-14
   PubMed Web of Science ®Google Scholar
• Santos CC, Lionel JR, Peres RB, et al. In vitro, in silico, and in vivo analyses of novel aromatic amidines against Trypanosoma cruzi. Antimicrob Agents Chemother. 2018;62:2. doi:10.1128/AAC.02205-17
   Web of Science ®Google Scholar
• Saccoliti F, Di Santo R, Costi R. Recent advancement in the search of innovative antiprotozoal agents targeting trypanothione metabolism. ChemMedChem. 2020;cmdc.202000325. doi:10.1002/cmdc.202000325
   Web of Science ®Google Scholar
• de Moreira TLB, Barbosa AFS, Veiga-Santos P, et al. Effect of thiazolidine LPSF SF29 on the growth and morphology of Trypanosoma cruzi. Int J Antimicrob Agents. 2013;41(2):183–187. doi:10.1016/j.ijantimicag.2012.09.018
   Web of Science ®Google Scholar
• Olmo F, Cussó O, Marín C, et al. In vitro and in vivo identification of tetradentated polyamine complexes as highly efficient metallodrugs against Trypanosoma cruzi. Exp Parasitol. 2016;164:20–30. doi:10.1016/j.exppara.2016.02.004
   PubMed Web of Science ®Google Scholar
• Martín-Escolano R, Cebrián R, Maqueda M, et al. Assessing the effectiveness of AS-48 in experimental mice models of Chagas’ disease. J Antimicrob Chemother. 2020;75(6):1537–1545. doi:10.1093/jac/dkaa030
   Web of Science ®Google Scholar
• Martín-Escolano R, Cebrián R, Martín-Escolano J, et al. Insights into Chagas treatment based on the potential of bacteriocin AS-48. Int J Parasitol Drugs Drug Resist. 2019;10:1–8. doi:10.1016/j.ijpddr.2019.03.003
   PubMed Web of Science ®Google Scholar
• Paixão DA, Lopes CD, Carneiro ZA, et al. In vitro anti-Trypanosoma cruzi activity of ternary copper(II) complexes and in vivo evaluation of the most promising complex. Biomed Pharmacother. 2019;109:157–166. doi:10.1016/j.biopha.2018.10.057
   Web of Science ®Google Scholar
• Guedes PMM, Oliveira FS, Gutierrez FRS, et al. Nitric oxide donor trans-[RuCl([15]aneN)NO] as a possible therapeutic approach for Chagas’ disease. Br J Pharmacol. 2010;160(2):270–282. doi:10.1111/j.1476-5381.2009.00576.x
   PubMed Web of Science ®Google Scholar
• Silva JJN, Guedes PMM, Zottis A, et al. Novel ruthenium complexes as potential drugs for Chagas’s disease: enzyme inhibition and in vitro/in vivo trypanocidal activity. Br J Pharmacol. 2010;160(2):260–269. doi:10.1111/j.1476-5381.2009.00524.x
   Web of Science ®Google Scholar
• Silva JJN, Pavanelli WR, Pereira JCM, Silva JS, Franco DW. Experimental chemotherapy against Trypanosoma cruzi infection using ruthenium nitric oxide donors. AAC. 2009;53(10):4414–4421. doi:10.1128/AAC.00104-09
   Web of Science ®Google Scholar
• Silva JJN, Osakabe AL, Pavanelli WR, Silva JS, Franco DW. In vitro and in vivo antiproliferative and trypanocidal activities of ruthenium NO donors. Br J Pharmacol. 2007;152(1):112–121. doi:10.1038/sj.bjp.0707363
   Web of Science ®Google Scholar
• Neitz RJ, Chen S, Supek F, et al. Lead identification to clinical candidate selection: drugs for Chagas disease. J Biomol Screen. 2015;20(1):101–111. doi:10.1177/1087057114553103
   PubMed Web of Science ®Google Scholar
• Hulpia F, Van Hecke K, da França Silva C, et al. Discovery of Novel 7-Aryl 7-Deazapurine 3′-deoxy-ribofuranosyl nucleosides with potent activity against Trypanosoma cruzi. J Med Chem. 2018;61(20):9287–9300. doi:10.1021/acs.jmedchem.8b00999
   PubMed Web of Science ®Google Scholar
• Lin C, Hulpia F, da Silva CF, et al. Discovery of Pyrrolo[2,3- b]pyridine (1,7-Dideazapurine) nucleoside analogues as anti- trypanosoma cruzi agents. J Med Chem. 2019;62(19):8847–8865. doi:10.1021/acs.jmedchem.9b01275
   PubMed Web of Science ®Google Scholar
• Aguirre-Alvarado C, Zaragoza-Martínez F, Rodríguez-Páez L, et al. Trypanocidal activity of the ethyl esters of N-propyl and N-isopropyl oxamates on intracellular amastigotes of Trypanosoma cruzi acute infected mice. J Enzyme Inhib Med Chem. 2010;25(1):111–115. doi:10.3109/14756360903027741
   PubMed Web of Science ®Google Scholar
• Chena MA, Elizondo S, Rodríguez-Páez L, Nogueda B, Baeza I, Wong C. Trypanocidal activity of N-isopropyl oxamate on cultured epimastigotes and murine trypanosomiasis using different Trypanosoma cruzi strains. J Enzyme Inhib Med Chem. 2005;20(2):189–197. doi:10.1080/14756360500047019
   PubMed Web of Science ®Google Scholar
• Wong-Baeza C, Nogueda-Torres B, Serna M, Meza-Toledo S, Baeza I, Wong C. Trypanocidal effect of the benzyl ester of N-propyl oxamate: a bi-potential prodrug for the treatment of experimental Chagas disease. BMC Pharmacol Toxicol. 2015;16:10. doi:10.1186/s40360-015-0010-4
   Web of Science ®Google Scholar
• Nefertiti ASG, Batista MM, Da Silva PB, et al. In vitro and in vivo studies of the trypanocidal effect of novel quinolines. Antimicrob Agents Chemother. 2017;62(2):e01936–17. doi:10.1128/AAC.01936-17
   Web of Science ®Google Scholar
• Vasconcelos JF, Meira CS, Silva DN, et al. Therapeutic effects of sphingosine kinase inhibitor N,N-dimethylsphingosine (DMS) in experimental chronic Chagas disease cardiomyopathy. Sci Rep. 2017;7(1):6171. doi:10.1038/s41598-017-06275-z
   Web of Science ®Google Scholar
• Olmo F, Rotger C, Ramírez-Macías I, et al. Synthesis and biological evaluation of N,N’-squaramides with high in vivo efficacy and low toxicity: toward a low-cost drug against Chagas disease. J Med Chem. 2014;57(3):987–999. doi:10.1021/jm4017015
   PubMed Web of Science ®Google Scholar
• Nagendar P, Gillespie JR, Herbst ZM, et al. Triazolopyrimidines and imidazopyridines: structure–activity relationships and in vivo efficacy for trypanosomiasis. ACS Med Chem Lett. 2019;10(1):105–110. doi:10.1021/acsmedchemlett.8b00498
   PubMed Web of Science ®Google Scholar
• Khare S, Nagle AS, Biggart A, et al. Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness. Nature. 2016;537(7619):229–233. doi:10.1038/nature19339
   PubMed Web of Science ®Google Scholar
• Diniz de LF, Caldas IS, da Guedes PM Met al. Effects of Ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi. AAC. 2010;54(7):2979–2986. doi:10.1128/AAC.01742-09
   Web of Science ®Google Scholar
• Urbina JA, Payares G, Sanoja C, Lira R, Romanha AJ. In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Int J Antimicrob Agents. 2003;21(1):27–38. doi:10.1016/S0924-8579(02)00273-X
   PubMed Web of Science ®Google Scholar
• da Diniz LF, Mazzeti AL, Caldas IS, Ribeiro I, Bahia MT. Outcome of E1224-benznidazole combination treatment for infection with a multidrug-resistant trypanosoma cruzi strain in mice. Antimicrob Agents Chemother. 2018;62(6):e00401–18. doi:10.1128/AAC.00401-18
   Web of Science ®Google Scholar
• Guedes-da-silva FH, Da batista GJ, Da Silva CF, et al. Successful aspects of the coadministration of Sterol 14α-Demethylase Inhibitor VFV and benznidazole in experimental mouse models of chagas disease caused by the drug-resistant strain of Trypanosoma cruzi. ACS Infect Dis. 2019;5(3):365–371. doi:10.1021/acsinfecdis.8b00253
   PubMed Web of Science ®Google Scholar
• Bastos JK, Albuquerque S, Silva MLA. Evaluation of the Trypanocidal activity of lignans isolated from the leaves of zanthoxylum naranjillo. Planta Med. 1999;65(6):541–544. doi:10.1055/s-1999-14012
   PubMed Web of Science ®Google Scholar
• Ferreira ME, Nakayama H, de Arias AR, et al. Effects of canthin-6-one alkaloids from Zanthoxylum chiloperone on Trypanosoma cruzi-infected mice. J Ethnopharmacol. 2007;109(2):258–263. doi:10.1016/j.jep.2006.07.028
   PubMed Web of Science ®Google Scholar
• Jimenez-Coello M, Acosta-Viana KY, Guzman-Marin E, Perez Gonzalez C, Salud Perez GM. Anti-trypanosomal activity of (8-hydroxymethylen)-trieicosanyl acetate against infective forms of Trypanosoma cruzi. Pharm Biol. 2010;48(6):666–671. doi:10.3109/13880200903241853
   PubMed Web of Science ®Google Scholar
• Ferreira ME, Cebrián-Torrejón G, Corrales AS, et al. Zanthoxylum chiloperone leaves extract: first sustainable Chagas disease treatment. J Ethnopharmacol. 2011;133(3):986–993. doi:10.1016/j.jep.2010.11.032
   PubMed Web of Science ®Google Scholar
• Marín C, Ramírez-Macías I, López-Céspedes A, et al. In vitro and in vivo trypanocidal activity of flavonoids from Delphinium staphisagria against Chagas disease. J Nat Prod. 2011;74(4):744–750. doi:10.1021/np1008043
   PubMed Web of Science ®Google Scholar
• Jiménez-Coello M, Acosta-Viana K, Pérez M, Del Guzmán-Marín S. In vivo activity of (8-Hydroxymethylen)-Trieicosanyl Acetate against Trypanosoma cruzi during acute phase of the infection. Afr J Trad Compl Alt Med. 2011;8(5S). doi:10.4314/ajtcam.v8i5S.26
   Google Scholar
• Meira CS, Guimarães ET, Bastos TM, et al. Physalins B and F, seco-steroids isolated from Physalis angulata L., strongly inhibit proliferation, ultrastructure and infectivity of Trypanosoma cruzi. Parasitology. 2013;140(14):1811–1821. doi:10.1017/S0031182013001297
   Web of Science ®Google Scholar
• Jimenez-Coello M, Acosta-Viana KY, Ortega-Pacheco A, Perez-Gutierrez S, In Vivo G-ME. Antiprotozoal activity of the chloroform extract from carica papaya seeds against amastigote stage of trypanosoma cruzi during indeterminate and chronic phase of infection. Evid Based Complement Alternat Med. 2014;2014:458263. doi:10.1155/2014/458263
   Web of Science ®Google Scholar
• Varela J, Serna E, Torres S, et al. In vivo anti-Trypanosoma cruzi activity of hydro-ethanolic extract and isolated active principles from Aristeguietia glutinosa and mechanism of action studies. Molecules. 2014;19(6):8488–8502. doi:10.3390/molecules19068488
   Web of Science ®Google Scholar
• da Rocha CQ, Queiroz EF, Meira CS, et al. Dimeric flavonoids from Arrabidaea brachypoda and assessment of their anti-Trypanosoma cruzi activity. J Nat Prod. 2014;77(6):1345–1350. doi:10.1021/np401060j
   PubMed Web of Science ®Google Scholar
• Meira CS, Guimarães ET, Jaf DS, et al. In vitro and in vivo antiparasitic activity of Physalis angulata L. concentrated ethanolic extract against Trypanosoma cruzi. Phytomedicine. 2015;22(11):969–974. doi:10.1016/j.phymed.2015.07.004
   Web of Science ®Google Scholar
• Lozano E, Strauss M, Spina R, et al. The in vivo trypanocidal effect of the diterpene 5-epi-icetexone obtained from Salvia gilliesii. Parasitol Int. 2016;65(1):23–26. doi:10.1016/j.parint.2015.08.011
   PubMed Web of Science ®Google Scholar
• García-Huertas P, Olmo F, Sánchez-Moreno M, Dominguez J, Chahboun R, Triana-Chávez O. Activity in vitro and in vivo against Trypanosoma cruzi of a furofuran lignan isolated from Piper jericoense. Exp Parasitol. 2018;189:34–42. doi:10.1016/j.exppara.2018.04.009
   PubMed Web of Science ®Google Scholar
• Tempone AG, Sartorelli P, Mady C, Fernandes F. Natural products to anti-trypanosomal drugs: an overview of new drug prototypes for American Trypanosomiasis. Cardiovasc Hematol Agents Med Chem. 2007;5(3):222–235. doi:10.2174/187152507781058726
   Google Scholar
• Varela J, Cerecetto H, Slowed GM. Development of natural products for chagas disease, how to move forward?. In: Nissapatorn V, Oz HS editors. . Chagas Disease - Basic Investigations and Challenges. InTech;2018. doi:10.5772/intechopen.77234
   Google Scholar
• Llurba Montesino N, Kaiser M, Brun R, Schmidt TJ. Search for antiprotozoal activity in herbal medicinal preparations; new natural leads against neglected tropical diseases. Molecules. 2015;20(8):14118–14138. doi:10.3390/molecules200814118
   Web of Science ®Google Scholar
• Mishina YV, Krishna S, Haynes RK, Meade JC. Artemisinins inhibit Trypanosoma cruzi and Trypanosoma brucei rhodesiense in vitro growth. AAC. 2007;51(5):1852–1854. doi:10.1128/AAC.01544-06
   Web of Science ®Google Scholar
• Chadwick M, Trewin H, Gawthrop F, Sesquiterpenoids Lactones: WC. Benefits to plants and people. Int J Mol Sci. 2013;14(6):12780–12805. doi:10.3390/ijms140612780
   PubMed Web of Science ®Google Scholar
• Branquinho RT, Mosqueira VCF, de Oliveira-silva JCV, Simões-Silva MR, Saúde-Guimarães DA, de Lana M. Sesquiterpene lactone in nanostructured parenteral dosage form is efficacious in experimental Chagas disease. Antimicrob Agents Chemother. 2014;58(4):2067–2075. doi:10.1128/AAC.00617-13
   PubMed Web of Science ®Google Scholar
• Cgc DM, Branquinho RT, Oliveira MT, et al. Efficacy of lychnopholide polymeric nanocapsules after oral and intravenous administration in murine experimental chagas disease. Antimicrob Agents Chemother. 2016;60(9):5215–5222. doi:10.1128/AAC.00178-16
   Web of Science ®Google Scholar
• Branquinho RT, Roy J, Farah C, et al. Biodegradable polymeric nanocapsules prevent cardiotoxicity of anti-Trypanosomal Lychnopholide. Sci Rep. 2017;7:44998. doi:10.1038/srep44998
   Web of Science ®Google Scholar
• Laurella LC, Cerny N, Bivona AE, et al. Assessment of sesquiterpene lactones isolated from Mikania plants species for their potential efficacy against Trypanosoma cruzi and Leishmania sp. Schallig HDFH, ed. PLoS Negl Trop Dis. 2017;11(9):e0005929. doi:10.1371/journal.pntd.0005929
   PubMed Web of Science ®Google Scholar
• Alberti AS, Cerny N, Bivona A, Cazorla SI. Antitrypanosomal and antileishmanial activities. In: Sülsen VP, Martino VS editors. Sesquiterpene Lactones. Springer International Publishing; 2018:175–196. doi:10.1007/978-3-319-78274-4_8.
   Google Scholar
• Gonçalves-Santos E, Vilas-Boas DF, Diniz LF, et al. Sesquiterpene lactone potentiates the immunomodulatory, antiparasitic and cardioprotective effects on anti-Trypanosoma cruzi specific chemotherapy. Int Immunopharmacol. 2019;77:105961. doi:10.1016/j.intimp.2019.105961
   PubMed Web of Science ®Google Scholar
• Branquinho RT, de Mello CGC, Oliveira MT, et al. Lychnopholide in Poly(D,L-Lactide)- Block -polyethylene glycol nanocapsules cures infection with a drug-resistant Trypanosoma cruzi strain at acute and chronic phases. Antimicrob Agents Chemother. 2020;64(4):e01937. doi:10.1128/AAC.01937-19
   Web of Science ®Google Scholar
• Milagre MM, Branquinho RT, Gonçalves MF, et al. Activity of the sesquiterpene lactone goyazensolide against Trypanosoma cruzi in vitro and in vivo. Parasitology. 2020;147(1):108–119. doi:10.1017/S0031182019001276
   PubMed Web of Science ®Google Scholar
• McCabe RE, Remington JS, Araujo FG. In vitro and in vivo effects of itraconazole against Trypanosoma cruzi. Am J Trop Med Hyg. 1986;35(2):280–284. doi:10.4269/ajtmh.1986.35.280
   PubMed Web of Science ®Google Scholar
• McCabe RE, Remington JS, Araujo FG. Ketoconazole promotes parasitological cure of mice infected with Trypanosoma cruzi. Trans R Soc Trop Med Hyg. 1987;81(4):613–615. doi:10.1016/0035-9203(87)90430-5
   PubMed Web of Science ®Google Scholar
• Goad LJ, Berens RL, Marr JJ, Beach DH, Holz GG. The activity of ketoconazole and other azoles against Trypanosoma cruzi: biochemistry and chemotherapeutic action in vitro. Mol Biochem Parasitol. 1989;32(2–3):179–189. doi:10.1016/0166-6851(89)90069-8
   PubMed Web of Science ®Google Scholar
• Lazardi K, Urbina JA, de Souza W. Ultrastructural alterations induced by two ergosterol biosynthesis inhibitors, ketoconazole and terbinafine, on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob Agents Chemother. 1990;34(11):2097–2105. doi:10.1128/aac.34.11.2097
   Web of Science ®Google Scholar
• Araujo MSS, Martins-Filho OA, Pereira MES, Brener Z. A combination of benznidazole and ketoconazole enhances efficacy of chemotherapy of experimental Chagas’ disease. J Antimicrob Chemother. 2000;45(6):819–824. doi:10.1093/jac/45.6.819
   PubMed Web of Science ®Google Scholar
• Molina J. In vivo activity of the bis-triazole D0870 against drug-susceptible and drug-resistant strains of the protozoan parasite Trypanosoma cruzi. J Antimicrob Chemother. 2000;46(1):137–140. doi:10.1093/jac/46.1.137
   PubMed Web of Science ®Google Scholar
• de Toledo O, Bahia MT, Carneiro CMet al. Chemotherapy with benznidazole and itraconazole for mice infected with different Trypanosoma cruzi clonal genotypes. Antimicrob Agents Chemother. 2003;47(1):223–230. doi:10.1128/aac.47.1.223-230.2003
   Web of Science ®Google Scholar
• da Guedes PMM, Urbina JA, de Lana Met al. Activity of the New Triazole Derivative Albaconazole against Trypanosoma (Schizotrypanum) cruzi in Dog Hosts. AAC. 2004;48(11):4286–4292. doi:10.1128/AAC.48.11.4286-4292.2004
   Web of Science ®Google Scholar
• Benaim G, Sanders JM, Garcia-Marchán Y, et al. Amiodarone has intrinsic anti- Trypanosoma cruzi activity and acts synergistically with posaconazole †. J Med Chem. 2006;49(3):892–899. doi:10.1021/jm050691f
   Web of Science ®Google Scholar
• Cencig S, Coltel N, Truyens C, Carlier Y. Evaluation of benznidazole treatment combined with nifurtimox, posaconazole or AmBisome® in mice infected with Trypanosoma cruzi strains. Int J Antimicrob Agents. 2012;40(6):527–532. doi:10.1016/j.ijantimicag.2012.08.002
   PubMed Web of Science ®Google Scholar
• de Diniz L F, Urbina JA, de Andrade IMet al. Benznidazole and posaconazole in experimental chagas disease: positive interaction in concomitant and sequential treatments. Rodrigues MM, ed. PLoS Negl Trop Dis. 2013;7(8):e2367. doi:10.1371/journal.pntd.0002367.
   Web of Science ®Google Scholar
• Assíria Fontes Martins T, de Figueiredo Diniz L, Mazzeti AL, et al. Benznidazole/Itraconazole combination treatment enhances anti-trypanosoma cruzi activity in experimental chagas disease. Costa FTM, ed. PLoS ONE. 2015;10(6):e0128707. doi:10.1371/journal.pone.0128707
   Web of Science ®Google Scholar
• Buckner FS, Bahia MT, Suryadevara PK, et al. Pharmacological characterization, structural studies, and in vivo activities of anti-chagas disease lead compounds derived from Tipifarnib. Antimicrob Agents Chemother. 2012;56(9):4914–4921. doi:10.1128/AAC.06244-11
   PubMed Web of Science ®Google Scholar
• Hucke O, Gelb MH, Verlinde CLMJ, Buckner FS. The protein farnesyltransferase inhibitor tipifarnib as a new lead for the development of drugs against Chagas Disease. J Med Chem. 2005;48(17):5415–5418. doi:10.1021/jm050441z
   PubMed Web of Science ®Google Scholar
• Kraus JM, Tatipaka HB, McGuffin SA, et al. Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-chagas disease drug discovery. J Med Chem. 2010;53(10):3887–3898. doi:10.1021/jm9013136
   PubMed Web of Science ®Google Scholar
• Bellera CL, Balcazar DE, Vanrell MC, et al. Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir. Eur J Med Chem. 2015;93:338–348. doi:10.1016/j.ejmech.2015.01.065
   PubMed Web of Science ®Google Scholar
• Sbaraglini ML, Bellera CL, Fraccaroli L, et al. Novel cruzipain inhibitors for the chemotherapy of chronic Chagas disease. Int J Antimicrob Agents. 2016;48(1):91–95. doi:10.1016/j.ijantimicag.2016.02.018
   PubMed Web of Science ®Google Scholar
• Benaim G, Paniz-Mondolfi AE, Sordillo EM, Martinez-Sotillo N. Disruption of intracellular calcium homeostasis as a therapeutic target against Trypanosoma cruzi. Front Cell Infect Microbiol. 2020;10:46. doi:10.3389/fcimb.2020.00046
   Web of Science ®Google Scholar
• Sbaraglini ML, Bellera CL, Quarroz Braghini J, et al. Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease. Eur J Med Chem. 2019;184:111778. doi:10.1016/j.ejmech.2019.111778
   PubMed Web of Science ®Google Scholar
• Simões-Silva MR, De Araújo JS, Peres RB, et al. Repurposing strategies for Chagas disease therapy: the effect of imatinib and derivatives against Trypanosoma cruzi. Parasitology. 2019;146(8):1006–1012. doi:10.1017/S0031182019000234
   PubMed Web of Science ®Google Scholar
• Ferreira DD, Mesquita JT, da Costa Silva TA, et al. Efficacy of sertraline against Trypanosoma cruzi: an in vitro and in silico study. J Venom Anim Toxins Incl Trop Dis. 2018;24:30. doi:10.1186/s40409-018-0165-8
   Web of Science ®Google Scholar
• Planer JD, Hulverson MA, Arif JA, Ranade RM, Don R, Buckner FS. Synergy testing of FDA-approved drugs identifies potent drug combinations against Trypanosoma cruzi. PLoS Negl Trop Dis. 2014;8(7):e2977. doi:10.1371/journal.pntd.0002977
   PubMed Web of Science ®Google Scholar
• Marr JJ, Berens RL, Nelson DJ. Antitrypanosomal effect of allopurinol: conversion in vivo to aminopyrazolopyrimidine nucleotides by Trypanosoma curzi. Science. 1978;201(4360):1018–1020. doi:10.1126/science.356267
   PubMed Web of Science ®Google Scholar
• Avila J, Avila A. Trypanosoma cruzi: allopurinol in the treatment of mice with experimental acute Chagas disease. Exp Parasitol. 1981;51(2):204–208. doi:10.1016/0014-4894(81)90109-0
   Web of Science ®Google Scholar
• Gobbi P, Lo Presti MS, Fernández AR, et al. Allopurinol is effective to modify the evolution of Trypanosoma cruzi infection in mice. Parasitol Res. 2007;101(5):1459–1462. doi:10.1007/s00436-007-0644-2
   PubMed Web of Science ®Google Scholar
• Raviolo MA, Solana ME, Novoa MM, Gualdesi MS, Alba-Soto CD, Briñón MC. Synthesis, physicochemical properties of allopurinol derivatives and their biological activity against Trypanosoma cruzi. Eur J Med Chem. 2013;69:455–464. doi:10.1016/j.ejmech.2013.08.045
   PubMed Web of Science ®Google Scholar
• Mazzeti AL, de Diniz LF, Gonçalves KR, et al. Synergic effect of allopurinol in combination with nitroheterocyclic compounds against Trypanosoma cruzi. Antimicrob Agents Chemother. 2019;63(6):e02264–18. doi:10.1128/AAC.02264-18
   Web of Science ®Google Scholar
• da Silva MTA, Silva-Jardim I, Portapilla GB, et al. In vivo and in vitro auranofin activity against Trypanosoma cruzi: possible new uses for an old drug. Exp Parasitol. 2016;166:189–193. doi:10.1016/j.exppara.2015.05.012
   Web of Science ®Google Scholar
• Rivarola HW, Bustamante JM, Lo Presti S, et al. Trypanosoma cruzi: chemotherapeutic effects of clomipramine in mice infected with an isolate obtained from an endemic area. Exp Parasitol. 2005;111(2):80–86. doi:10.1016/j.exppara.2005.05.005
   Web of Science ®Google Scholar
• Fauro R, Lo Presti S, Bazan C, et al. Use of clomipramine as chemotherapy of the chronic phase of Chagas disease. Parasitology. 2013;140(7):917–927. doi:10.1017/S0031182013000103
   PubMed Web of Science ®Google Scholar
• Cunha ELA, da Torchelsen FKVS, Cunha LM, et al. Benznidazole, itraconazole and their combination in the treatment of acute experimental chagas disease in dogs. Exp Parasitol. 2019;204:107711. doi:10.1016/j.exppara.2019.05.005
   PubMed Web of Science ®Google Scholar
• Moreira da Silva R, Oliveira LT, Silva Barcellos NM, de Souza J, de Lana M. Preclinical monitoring of drug association in experimental chemotherapy of chagas’ disease by a new HPLC-UV method. Antimicrob Agents Chemother. 2012;56(6):3344–3348. doi:10.1128/AAC.05785-11
   PubMed Web of Science ®Google Scholar
• Cunha ELA, da Torchelsen FKVS, Cunha LM, et al. Benznidazole, itraconazole and their combination in the treatment of acute experimental Chagas disease in dogs. MethodsX. 2019;6:2544–2552. doi:10.1016/j.mex.2019.10.007
   PubMed Web of Science ®Google Scholar
• Echeverría LE, González CI, Hernandez JCM, et al. Efficacy of the Benznidazole+Posaconazole combination therapy in parasitemia reduction: an experimental murine model of acute Chagas. Rev Soc Bras Med Trop. 2020;53:e20190477. doi:10.1590/0037-8682-0477-2019
   PubMed Web of Science ®Google Scholar
• Gulin JEN, Eagleson MA, López-Muñoz RA, Solana ME, Altcheh J, García-Bournissen F. In vitro and in vivo activity of voriconazole and benznidazole combination on trypanosoma cruzi infection models. Acta Trop. 2020;211:105606. doi:10.1016/j.actatropica.2020.105606
   PubMed Web of Science ®Google Scholar
• Rial MS, Scalise ML, López Alarcón M, et al. Experimental combination therapy using low doses of benznidazole and allopurinol in mouse models of Trypanosoma cruzi chronic infection. Parasitology. 2019;146(3):305–313. doi:10.1017/S0031182018001567
   PubMed Web of Science ®Google Scholar
• Grosso NL, Alarcon ML, Bua J, Laucella SA, Riarte A, Fichera LE. Combined treatment with benznidazole and allopurinol in mice infected with a virulent Trypanosoma cruzi isolate from Nicaragua. Parasitology. 2013;140(10):1225–1233. doi:10.1017/S0031182013000176
   PubMed Web of Science ®Google Scholar
• Veiga-Santos P, Barrias ES, Santos JFC, et al. Effects of amiodarone and posaconazole on the growth and ultrastructure of Trypanosoma cruzi. Int J Antimicrob Agents. 2012;40(1):61–71. doi:10.1016/j.ijantimicag.2012.03.009
   PubMed Web of Science ®Google Scholar
• Strauss M, Lo Presti MS, Bazán PC, et al. Clomipramine and benznidazole association for the treatment of acute experimental Trypanosoma cruzi infection. Parasitol Int. 2013;62(3):293–299. doi:10.1016/j.parint.2013.02.004
   Web of Science ®Google Scholar
• Cevey ÁC, Mirkin GA, Donato M, et al. Treatment with Fenofibrate plus a low dose of Benznidazole attenuates cardiac dysfunction in experimental Chagas disease. Int J Parasitol Drugs Drug Resist. 2017;7(3):378–387. doi:10.1016/j.ijpddr.2017.10.003
   Web of Science ®Google Scholar
• González-Herrera F, Cramer A, Pimentel P, et al. Simvastatin attenuates endothelial activation through 15-Epi-Lipoxin A4 production in murine chronic chagas cardiomyopathy. Antimicrob Agents Chemother. 2017;61(3):e02137-16, e02137-16. doi:10.1128/AAC.02137-16
   Web of Science ®Google Scholar
• Santeliz S, Caicedo P, Giraldo E, et al. Dipyridamole potentiated the trypanocidal effect of nifurtimox and improved the cardiac function in NMRI mice with acute chagasic myocarditis. Mem Inst Oswaldo Cruz. 2017;112(9):596–608. doi:10.1590/0074-02760160499
   Web of Science ®Google Scholar
• Providello MV, Carneiro ZA, Portapilla GB, et al. Benefits of ascorbic acid in association with low-dose benznidazole in treatment of chagas disease. Antimicrob Agents Chemother. 2018;62(9):e00514–18. doi:10.1128/AAC.00514-18
   PubMed Web of Science ®Google Scholar
• Strauss M, Rodrigues JHS, Lo Presti MS, et al. In vitro and in vivo drug combination for the treatment of Trypanosoma cruzi infection: a multivariate approach. Exp Parasitol. 2018;189:19–27. doi:10.1016/j.exppara.2018.04.016
   Web of Science ®Google Scholar
• Madigan R, Majoy S, Ritter K, et al. Investigation of a combination of amiodarone and itraconazole for treatment of American trypanosomiasis (Chagas disease) in dogs. J Am Vet Med Assoc. 2019;255(3):317–329. doi:10.2460/javma.255.3.317
   PubMed Web of Science ®Google Scholar
• Sass G, Madigan RT, Joubert L-M, et al. A combination of itraconazole and amiodarone is highly effective against trypanosoma cruzi infection of human stem cell-derived cardiomyocytes. Am J Trop Med Hyg. 2019;101(2):383–391. doi:10.4269/ajtmh.19-0023
   PubMed Web of Science ®Google Scholar
• Rocha Simões-Silva M, Brandão peres R, Britto C, et al. Impact of levamisole in co-administration with benznidazole on experimental Chagas disease. Parasitology. 2019;146(8):1055–1062. doi:10.1017/S0031182019000374
   Web of Science ®Google Scholar
• Pereira RS, Malvezi AD, Lovo-Martins MI, et al. Combination therapy using benznidazole and aspirin during the acute phase of experimental chagas disease prevents cardiovascular dysfunction and decreases typical cardiac lesions in the chronic Phase. Antimicrob Agents Chemother. 2020;64(7):e00069–20. doi:10.1128/AAC.00069-20
   Web of Science ®Google Scholar
• Machado YA, Bahia MT, Caldas IS, et al. Amlodipine increases the therapeutic potential of ravuconazole upon Trypanosoma cruzi Infection. Antimicrob Agents Chemother. 2020;64(8):e02497–19. doi:10.1128/AAC.02497-19
   Web of Science ®Google Scholar
• DNDi. The BENDITA study | DNDi. Drugs for Neglected Diseases initiative (DNDi). 2019. Accessed December 16, 2020. https://dndi.org/publications/2019/bendita-study/
   Google Scholar
• Filardi LS, Brener Z. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans R Soc Trop Med Hyg. 1987;81(5):755–759. doi:10.1016/0035-9203(87)90020-4
   PubMed Web of Science ®Google Scholar
• Rial MS, Arrúa EC, Natale MA, et al. Efficacy of continuous versus intermittent administration of nanoformulated benznidazole during the chronic phase of Trypanosoma cruzi Nicaragua infection in mice. J Antimicrob Chemother. 2020;75(7):1906–1916. doi:10.1093/jac/dkaa101
   PubMed Web of Science ®Google Scholar
• Perin L, da Fonseca KS, De Carvalho TV, et al. Low-dose of benznidazole promotes therapeutic cure in experimental chronic Chagas’ disease with absence of parasitism in blood, heart and colon. Exp Parasitol. 2020;210:107834. doi:10.1016/j.exppara.2020.107834
   PubMed Web of Science ®Google Scholar
• Bustamante JM, Sanchez-Valdez F, Padilla AM, White B, Wang W, Tarleton RL. A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease. Sci Transl Med. 2020;12:567. doi:10.1126/scitranslmed.abb7656
   Web of Science ®Google Scholar
• Molina I, Perin L, Aviles AS, et al. The effect of benznidazole dose among the efficacy outcome in the murine animal model. A quantitative integration of the literature. Acta Trop. 2020;201:105218. doi:10.1016/j.actatropica.2019.105218
   PubMed Web of Science ®Google Scholar
• Mazzeti AL, de Diniz LF, Gonçalves KR, et al. Time and dose-dependence evaluation of nitroheterocyclic drugs for improving efficacy following Trypanosoma cruzi infection: a pre-clinical study. Biochem Pharmacol. 2018;148:213–221. doi:10.1016/j.bcp.2018.01.005
   Web of Science ®Google Scholar
• Mosqueira VCF, Mazzeti AL, Bahia MT. Nanomedicines against Chagas disease. In: Applications of Nanobiotechnology for Neglected Tropical Diseases. Elsevier; 2021:169–189. doi:10.1016/B978-0-12-821100-7.00008-X
   Google Scholar
• Davies C, Simonazzi A, Micheloud JF, et al. Benznidazole/Poloxamer 407 solid dispersion as a new strategy to improve the treatment of experimental trypanosoma cruzi infection. J Parasitol. 2020;106(3):323–333. doi:10.1645/19-80
   Web of Science ®Google Scholar
• Manarin R, Lamas MC, Bottasso E, Serra E, Revelli S, Salomón CJ. Efficacy of novel benznidazole solutions during the experimental infection with Trypanosoma cruzi. Parasitol Int. 2013;62(1):79–81. doi:10.1016/j.parint.2012.09.001
   Web of Science ®Google Scholar
• Yardley V, Croft SL. In vitro and in vivo activity of amphotericin B-lipid formulations against experimental Trypanosoma cruzi infections. Am J Trop Med Hyg. 1999;61(2):193–197. doi:10.4269/ajtmh.1999.61.193
   PubMed Web of Science ®Google Scholar
• Cencig S, Coltel N, Truyens C, Carlier Y. Parasitic loads in tissues of mice infected with Trypanosoma cruzi and treated with AmBisome. PLoS Negl Trop Dis. 2011;5(6):e1216. doi:10.1371/journal.pntd.0001216
   Web of Science ®Google Scholar
• Clemons KV, Sobel RA, Martinez M, Correa-Oliveira R, Stevens DA. Lack of efficacy of liposomal Amphotericin B against acute and chronic Trypanosoma cruzi infection in mice. Am J Trop Med Hyg. 2017;97(4):1141–1146. doi:10.4269/ajtmh.16-0975
   Web of Science ®Google Scholar
• Morilla MJ, Montanari JA, Prieto MJ, Lopez MO, Petray PB, Romero EL. Intravenous liposomal benznidazole as trypanocidal agent: increasing drug delivery to liver is not enough. Int J Pharm. 2004;278(2):311–318. doi:10.1016/j.ijpharm.2004.03.025
   Web of Science ®Google Scholar
• Morilla MJ, Montanari J, Frank F, et al. Etanidazole in pH-sensitive liposomes: design, characterization and in vitro/in vivo anti-Trypanosoma cruzi activity. J Controlled Release. 2005;103(3):599–607. doi:10.1016/j.jconrel.2004.12.012
   PubMed Web of Science ®Google Scholar
• Oliveira LT, Mosqueira VCF, Castanheira R WO2015039199 Micro- and nanostructured pharmaceutical and veterinary compositions, containing benznidazole and derivatives thereof, which form micro- and nanostructures in the gastrointestinal tract, and biological uses thereof. Patent Scop e. 2014. Available from: https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2015039199 Accessed November 26, 2020.
   Google Scholar
• Spósito PÁF, Mazzeti Silva AL, De oliveira Faria C, et al. Ravuconazole self-emulsifying delivery system: in vitro activity against Trypanosoma cruzi amastigotes and in vivo toxicity. IJN. 2017;12:3785–3799. doi:10.2147/IJN.S133708
   Web of Science ®Google Scholar
• Mazzeti AL, Oliveira LT, Gonçalves KR, Schaun GC, Mosqueira VCF, Bahia MT. Benznidazole self-emulsifying delivery system: a novel alternative dosage form for Chagas disease treatment. Eur J Pharm Sci. 2020;145:105234. doi:10.1016/j.ejps.2020.105234
   PubMed Web of Science ®Google Scholar
• Esteva MI, Rial MS, Scalise ML, Fichera LE, Arrúa EC, Salomon CJ. Promising efficacy of benznidazole nanoparticles in acute Trypanosoma cruzi murine model: in-vitro and in-vivo studies. Am J Trop Med Hyg. 2016;95(2):388–393. doi:10.4269/ajtmh.15-0889
   PubMed Web of Science ®Google Scholar
• Abriata JP, Eloy JO, Riul TB, Campos PM, Baruffi MD, Marchetti JM. Poly-epsilon-caprolactone nanoparticles enhance ursolic acid in vivo efficacy against Trypanosoma cruzi infection. Mater Sci Eng C Mater Biol Appl. 2017;77:1196–1203. doi:10.1016/j.msec.2017.03.266
   Web of Science ®Google Scholar
• Saraiva J, Lira AAM, Esperandim VR, et al. (-)-Hinokinin-loaded poly(D,-lactide-co-glycolide) microparticles for Chagas disease. Parasitol Res. 2010;106(3):703–708. doi:10.1007/s00436-010-1725-1
   PubMed Web of Science ®Google Scholar
• Molina J. Cure of experimental Chagas’ disease by the bis-triazole DO870 incorporated into “stealth” polyethyleneglycol-polylactide nanospheres. J Antimicrob Chemother. 2001;47(1):101–104. doi:10.1093/jac/47.1.101
   Web of Science ®Google Scholar
• Rolón M, Serrano DR, Lalatsa A, et al. Engineering oral and parenteral amorphous Amphotericin B Formulations against experimental Trypanosoma cruzi infections. Mol Pharm. 2017;14(4):1095–1106. doi:10.1021/acs.molpharmaceut.6b01034
   Web of Science ®Google Scholar
• Parra FL, Frank FM, Alliani BF, Romero EL, Petray PB. Imiquimod-loaded nanoarchaeosomes as a promising immunotherapy against Trypanosoma cruzi infection. Colloids Surf B Biointerfaces. 2020;189:110850. doi:10.1016/j.colsurfb.2020.110850
   Web of Science ®Google Scholar
• Campos MCO, Leon LL, Taylor MC, Kelly JM. Benznidazole-resistance in Trypanosoma cruzi: evidence that distinct mechanisms can act in concert. Mol Biochem Parasitol. 2014;193(1):17–19. doi:10.1016/j.molbiopara.2014.01.002
   PubMed Web of Science ®Google Scholar
• Petravicius PO, Costa-Martins AG, Silva MN, et al. Mapping benznidazole resistance in trypanosomatids and exploring evolutionary histories of nitroreductases and ABCG transporter protein sequences. Acta Trop. 2019;200:105161. doi:10.1016/j.actatropica.2019.105161
   PubMed Web of Science ®Google Scholar
• Zingales B. Trypanosoma cruzi genetic diversity: something new for something known about Chagas disease manifestations, serodiagnosis and drug sensitivity. Acta Trop. 2018;184:38–52. doi:10.1016/j.actatropica.2017.09.017
   PubMed Web of Science ®Google Scholar
• Franco J, Ferreira RC, Ienne S, Zingales B. ABCG-like transporter of Trypanosoma cruzi involved in benznidazole resistance: gene polymorphisms disclose inter-strain intragenic recombination in hybrid isolates. Infect Genet Evol. 2015;31:198–208. doi:10.1016/j.meegid.2015.01.030
   Web of Science ®Google Scholar
• Murta SMF, Krieger MA, Montenegro LRet al. Deletion of copies of the gene encoding old yellow enzyme (TcOYE), a NAD(P)H flavin oxidoreductase, associates with in vitro-induced benznidazole resistance in Trypanosoma cruzi. Mol Biochem Parasitol. 2006;146(2):151–162. doi:10.1016/j.molbiopara.2005.12.001.
   Web of Science ®Google Scholar
• Nogueira FB, Krieger MA, Nirdé P, Goldenberg S, Romanha AJ, Murta SMF. Increased expression of iron-containing superoxide dismutase-A (TcFeSOD-A) enzyme in Trypanosoma cruzi population with in vitro-induced resistance to benznidazole. Acta Trop. 2006;100(1–2):119–132. doi:10.1016/j.actatropica.2006.10.004
   Web of Science ®Google Scholar
• Dumoulin PC, Vollrath J, Tomko SS, Wang JX, Burleigh B. Glutamine metabolism modulates azole susceptibility in Trypanosoma cruzi amastigotes. eLife. 2020;9:e60226. doi:10.7554/eLife.60226
   Web of Science ®Google Scholar
• Sánchez-Valdéz FJ, Padilla A, Wang W, Orr D, Tarleton RL. Spontaneous dormancy protects Trypanosoma cruzi during extended drug exposure. Elife. 2018;7. doi:10.7554/eLife.34039
   Web of Science ®Google Scholar
• Romanha AJ, de Castro SL, De Soeiro M, et al. In vitro and in vivo experimental models for drug screening and development for Chagas disease. Mem Inst Oswaldo Cruz. 2010;105(2):233–238. doi:10.1590/S0074-02762010000200022
   PubMed Web of Science ®Google Scholar
• Vannier-Santos MA, Brunoro VG, de Nazaré C, et al.. Parasite, compartments, and molecules: trick versus treatment on chagas disease. In: editor, De Souza W. Biology of Trypanosoma Cruzi. IntechOpen; 2019. doi:10.5772/intechopen.84472
   Google Scholar